2 results
Not approvedWill not start
The primary objective of this study is to demonstrate that the IOP-lowering efficacy of Travoprost Ophthalmic Solution, 0.004% (preserved with POLYQUAD) is noninferior to Timolol Ophthalmic Solution (0.5% or 0.25%) in pediatric glaucoma patients.
Approved WMOCompleted
Aim of the study is to ascertain the order of magnitude to which ESWT may improve the performance of specific activities of daily living (ADL), measured by Goal Entertainment Scaling (GAS) in people with spinal cord injury and spasticity in theā¦